几内亚一线工作人员参与埃博拉疫苗试验的影响因素
该定性研究于2015年7—8月在几内亚科纳克里开展焦点小组讨论和半结构化个人访谈,对象为符合免疫原性与安全性研究纳入标准者,共访谈110人,约67%参与了疫苗试验。参与者多因保护自己和他人、贡献科学进步或以身作则;未参与者担忧风险与成本,尤其害怕未知副作用及污名化。
要点
- 参与者动机包括保护自己和他人、贡献科学进步及以身作则。
- 未参与者担忧参与风险与成本,尤其害怕疫苗未知副作用。
- 未参与者存在不信任或对污名化的恐惧。
核心结论
- 尽管2014—2015年埃博拉疫情具有独特性,一线工作人员在选择是否参与时使用的逻辑与类似环境下其他临床试验大致相同。
- 未来试验应特别考虑解决目标人群中感知的不公平、误解和不信任。
研究设计与样本
- 在一项埃博拉疫苗一线工作人员免疫原性与安全性试验的同时开展定性研究。
- 2015年7月和8月在几内亚科纳克里进行焦点小组讨论和半结构化个人访谈。
- 符合免疫原性与安全性研究纳入标准者无论是否参与均可纳入定性研究。
- 还对参与研究的若干机构和部门负责人及疫苗试验工作人员进行了调查。
- 讨论和访谈转录稿采用内容主题分析。
主要发现
- 共对110人进行访谈和焦点小组,其中约三分之二(67%)参与了疫苗试验。
- 每个参与试验点至少进行了一组小组访谈,入组期间还有大量正式和非正式访谈及对话。
- 参与者常因希望拯救和保护自己及他人、贡献科学进步或以身作则而受到激励。
- 未参与者表达了对参与风险和成本的担忧,尤其是害怕接种疫苗后出现未知副作用。
- 未参与者还表达不信任或害怕被污名化。
临床怎么用
- 未来疫苗试验设计应关注并回应目标人群对参与风险与成本的担忧,尤其是对未知副作用的恐惧。
- 应特别考虑处理目标人群中感知的不公平、误解和不信任。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alongside the clinical aspects of the immunogenicity and safety trial of an Ebola vaccine deployed among front-line workers, a qualitative study was conducted to describe motivations behind individuals' decisions to participate - or not to participate - in the study. METHODS: In July and August 2015, focus group discussions and semi-structured individual interviews were conducted in Conakry, Guinea. Individuals were eligible for the qualitative study if they met the inclusion criteria of the immunogenicity and safety study irrespective of their participation. Surveys were also conducted among several institution and department heads of staff included in the study as well as vaccine trial staff members. Discussion and interview transcripts were analyzed using content thematic analysis. RESULTS: Interviews and focus groups were conducted among 110 persons, of whom about two-thirds (67%) participated in the vaccine trial. There was at least one group interview conducted at each participating trial site, along with numerous formal and informal interviews and conversations through the enrollment period. Participants were often motivated by a desire to save and protect themselves and others, contribute to scientific progress, or lead by example. Non-participants expressed concerns regarding the risk and costs of participation, particularly the fear of unknown side effects following vaccination, and distrust or fear of stigmatization. CONCLUSIONS: Despite the unique nature of the 2014-2015 Ebola outbreak, front-line workers employed much of the same logic when choosing to participate as in other clinical trials in similar settings. Special consideration should be given to addressing perceived inequity, misunderstanding, and mistrust among the target populations in future trials. Clinical trial registry number: This trial is registered with the Pan African Clinical Trials Registry, number PACTR201503001057193.
引用
- Grantz KH, Claudot P, Kambala M, et al. Factors influencing participation in an Ebola vaccine trial among front-line workers in Guinea. Vaccine. 2019. PMID: 31623917. doi:10.1016/j.vaccine.2019.09.094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。